S&P 500   3,796.74 (+1.23%)
DOW   30,676.06 (+1.23%)
QQQ   320.91 (+0.46%)
AAPL   141.20 (-0.61%)
MSFT   234.48 (+0.68%)
FB   276.67 (+1.66%)
GOOGL   1,830.00 (+0.61%)
AMZN   3,248.00 (+0.48%)
TSLA   833.29 (-3.57%)
NVDA   520.99 (+0.83%)
BABA   259.98 (-0.10%)
CGC   37.26 (-1.51%)
GE   11.45 (+0.62%)
MU   76.75 (+2.21%)
AMD   90.07 (+1.38%)
NIO   57.50 (+0.61%)
T   29.17 (+0.10%)
F   10.89 (+0.93%)
ACB   11.38 (+1.61%)
BA   197.57 (+1.82%)
DIS   165.52 (+1.53%)
NFLX   529.00 (+1.09%)
GILD   65.29 (-0.29%)
S&P 500   3,796.74 (+1.23%)
DOW   30,676.06 (+1.23%)
QQQ   320.91 (+0.46%)
AAPL   141.20 (-0.61%)
MSFT   234.48 (+0.68%)
FB   276.67 (+1.66%)
GOOGL   1,830.00 (+0.61%)
AMZN   3,248.00 (+0.48%)
TSLA   833.29 (-3.57%)
NVDA   520.99 (+0.83%)
BABA   259.98 (-0.10%)
CGC   37.26 (-1.51%)
GE   11.45 (+0.62%)
MU   76.75 (+2.21%)
AMD   90.07 (+1.38%)
NIO   57.50 (+0.61%)
T   29.17 (+0.10%)
F   10.89 (+0.93%)
ACB   11.38 (+1.61%)
BA   197.57 (+1.82%)
DIS   165.52 (+1.53%)
NFLX   529.00 (+1.09%)
GILD   65.29 (-0.29%)
S&P 500   3,796.74 (+1.23%)
DOW   30,676.06 (+1.23%)
QQQ   320.91 (+0.46%)
AAPL   141.20 (-0.61%)
MSFT   234.48 (+0.68%)
FB   276.67 (+1.66%)
GOOGL   1,830.00 (+0.61%)
AMZN   3,248.00 (+0.48%)
TSLA   833.29 (-3.57%)
NVDA   520.99 (+0.83%)
BABA   259.98 (-0.10%)
CGC   37.26 (-1.51%)
GE   11.45 (+0.62%)
MU   76.75 (+2.21%)
AMD   90.07 (+1.38%)
NIO   57.50 (+0.61%)
T   29.17 (+0.10%)
F   10.89 (+0.93%)
ACB   11.38 (+1.61%)
BA   197.57 (+1.82%)
DIS   165.52 (+1.53%)
NFLX   529.00 (+1.09%)
GILD   65.29 (-0.29%)
S&P 500   3,796.74 (+1.23%)
DOW   30,676.06 (+1.23%)
QQQ   320.91 (+0.46%)
AAPL   141.20 (-0.61%)
MSFT   234.48 (+0.68%)
FB   276.67 (+1.66%)
GOOGL   1,830.00 (+0.61%)
AMZN   3,248.00 (+0.48%)
TSLA   833.29 (-3.57%)
NVDA   520.99 (+0.83%)
BABA   259.98 (-0.10%)
CGC   37.26 (-1.51%)
GE   11.45 (+0.62%)
MU   76.75 (+2.21%)
AMD   90.07 (+1.38%)
NIO   57.50 (+0.61%)
T   29.17 (+0.10%)
F   10.89 (+0.93%)
ACB   11.38 (+1.61%)
BA   197.57 (+1.82%)
DIS   165.52 (+1.53%)
NFLX   529.00 (+1.09%)
GILD   65.29 (-0.29%)
Log in
NYSE:NVO

Novo Nordisk A/S Stock Forecast, Price & News

$70.50
+0.53 (+0.76 %)
(As of 01/28/2021 08:02 AM ET)
Add
Compare
Today's Range
$70.50
Now: $70.50
$70.50
50-Day Range
$68.72
MA: $70.93
$73.80
52-Week Range
$49.24
Now: $70.50
$73.92
Volume1 shs
Average Volume1.00 million shs
Market Capitalization$166.01 billion
P/E Ratio26.50
Dividend Yield1.01%
Beta0.46
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S logo

MarketRank

Overall MarketRank

1.40 out of 5 stars

Medical Sector

539th out of 1,926 stocks

Pharmaceutical Preparations Industry

273rd out of 772 stocks

Analyst Opinion: 2.0Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888
Employees44,326
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.30 billion
Cash Flow$2.81 per share
Book Value$3.65 per share

Profitability

Net Income$5.84 billion

Miscellaneous

Outstanding Shares2,354,800,000
Market Cap$166.01 billion
Next Earnings Date2/3/2021 (Estimated)
OptionableOptionable
$70.50
+0.53 (+0.76 %)
(As of 01/28/2021 08:02 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

How has Novo Nordisk A/S's stock price been impacted by Coronavirus?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVO stock has increased by 20.9% and is now trading at $69.97.
View which stocks have been most impacted by COVID-19
.

Is Novo Nordisk A/S a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Novo Nordisk A/S?

Wall Street analysts have given Novo Nordisk A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novo Nordisk A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Novo Nordisk A/S
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its earnings results on Wednesday, November, 4th. The company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.01. The company earned $4.86 billion during the quarter, compared to analyst estimates of $4.75 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 71.46% and a net margin of 32.65%.
View Novo Nordisk A/S's earnings history
.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a semi-annual dividend on Friday, August 7th. Investors of record on Monday, August 17th will be paid a dividend of $0.7826 per share on Tuesday, August 25th. This represents a yield of 1.4%. The ex-dividend date is Friday, August 14th.
View Novo Nordisk A/S's dividend history
.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.74 per share and currently has a dividend yield of 1.01%. The dividend payout ratio of Novo Nordisk A/S is 30.08%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 25.00% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2020 IntraDay earnings guidance on Friday, October, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20.115-20.69 billion, compared to the consensus revenue estimate of $20.39 billion.

What price target have analysts set for NVO?

9 brokers have issued 12-month target prices for Novo Nordisk A/S's stock. Their forecasts range from $72.00 to $72.00. On average, they anticipate Novo Nordisk A/S's stock price to reach $72.00 in the next year. This suggests a possible upside of 2.9% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S
or view Wall Street analyst' top-rated stocks.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 4,090,000 shares, a decrease of 17.9% from the December 15th total of 4,980,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is currently 3.6 days. Approximately 0.2% of the shares of the stock are short sold.
View Novo Nordisk A/S's Short Interest
.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:
  • Mr. Lars Fruergaard Jørgensen, Pres, CEO & Member of Management Board (Age 55)
  • Mr. Karsten Munk Knudsen, Exec. VP, CFO & Member of the Management Board (Age 50)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP, Chief Scientific Officer, Head of R&D and Member of the Management Board (Age 61)
  • Mr. Henrik Ehlers Wulff, Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board (Age 51)
  • Ms. Camilla Sylvest, Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board (Age 49)
  • Ms. Monique Carter, Exec. VP, Head of People & Organisation and Member of Management Board (Age 48)
  • Mr. Maziar Mike Doustdar, Exec. VP, Head of International Operations & Member of the Management Board (Age 51)
  • Mr. Douglas J. Langa, Exec. VP, Head of North America Operations & Member of Management Board (Age 55)
  • Mr. Ludovic Helfgott, Exec. VP, Head of Biopharm & Member of Management Board (Age 47)
  • Mr. Peter Hugreffe Ankersen, Head of Investor Relations & Corp. VP

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a number of institutional and retail investors. Top institutional investors include Calamos Advisors LLC (0.01%), QV Investors Inc. (0.01%), Penbrook Management LLC (0.01%), Scout Investments Inc. (0.01%), Janney Montgomery Scott LLC (0.01%) and CWM LLC (0.00%).
View institutional ownership trends for Novo Nordisk A/S
.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, QV Investors Inc., Scout Investments Inc., CWM LLC, Autus Asset Management LLC, Confluence Investment Management LLC, Avantax Advisory Services Inc., and Traynor Capital Management Inc..
View insider buying and selling activity for Novo Nordisk A/S
or view top insider-selling stocks.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was acquired by a variety of institutional investors in the last quarter, including Penbrook Management LLC, Chemung Canal Trust Co., Janney Montgomery Scott LLC, Kestra Advisory Services LLC, Keeler Thomas Management LLC, V Wealth Advisors LLC, Stillwater Investment Management LLC, and Palladiem LLC.
View insider buying and selling activity for Novo Nordisk A/S
or or view top insider-buying stocks.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $69.97.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $164.77 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis. Novo Nordisk A/S employs 44,326 workers across the globe.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.